$CCCC News

JP Morgan Initiates Coverage On C4 Therapeutics with Overweight Rating, Announces Price Target of $10

C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting

C4 Therapeutics Presents New Biomarker Data From Phase 1 Clinical Trial Of Cemsidomide In Combination With Dexamethasone In Patients With RRMM At 23rd IMS Annual Meeting

C4 Therapeutics: Priced For Perfection Ahead Of 2027 Cemsidomide Readouts

C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual Meeting

C4 Therapeutics To Present New Biomarker Data On Immunomodulatory Effects Of Cemsidomide In Combination With Dexamethasone From Phase 1 Trial For RRMM At IMS Annual Meeting

Are You Looking for a Top Momentum Pick? Why C4 Therapeutics, Inc. (CCCC) is a Great Choice

C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates

C4 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

C4 Therapeutics Q2 EPS $(0.18) Beats $(0.23) Estimate, Sales $6.641M Beat $4.000M Estimate

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

C4 Therapeutics, Inc. (CCCC) Is Up 2.65% in One Week: What You Should Know

C4 Therapeutics (CCCC) Gains Over the Past Month, Can It Go Higher?

C4 Therapeutics, Inc. (CCCC) Discusses Evolving Multiple Myeloma Treatments and the Role of IKZF1/3 Degraders Including Cemsidomide - Slideshow

C4 Therapeutics, Inc. (CCCC) Discusses Evolving Multiple Myeloma Treatments and the Role of IKZF1/3 Degraders Including Cemsidomide Transcript

Are Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?

C4 Therapeutics Reports 53% Response Rate for Cemsidomide at RP2D

C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population

C4 Therapeutics To Present Further Analysis From Fully Enrolled Phase 1 Trial Of Cemsidomide In Combination With Dexamethasone For Treatment Of RRMM At EHA 2026 Congress

C4 Therapeutics (CCCC) Upgraded to Buy: What Does It Mean for the Stock?